VANCOUVER, BC , Nov. 21, 2024 /PRNewswire/ -- Zero Candida Technologies Inc. (the "Company" or "Zero Candida") (TSXV: ZCT), a technology company focused on development and commercial exploitation of a number of patents and patent applications with respect to an AI smart tampon-like device, designed to treat Candidiasis and transfer the medical information via Wi-Fi to the doctor, is pleased to announce that its common shares (the "Common Shares") are expected to commence trading on the TSX Venture Exchange (the "TSXV") at the market opening on November 25, 2024 .
Zero Candida has recently completed its business acquisition of Zero Candida Ltd., an Israeli private company ("ZC" and "Acquisition" respectively). Following the completion of the Acquisition, the Company has a total of 19,533,037 Common Shares issued and outstanding.
Further details regarding the Company and the Acquisition are contained in the Company's TSXV Form 2B Listing Application, which is available under the Company's profile on SEDAR+ at www.sedarplus.ca .
About Zero Candida Zero Candida is focused on commercial exploitation of a number of patents and patent applications with respect to an AI smart tampon-like device, designed to treat Candidiasis and transfer the medical information via Wi-Fi to the doctor. ZC technology is a combination of a therapy light source with a selected wavelength and intensity and a transparent gel-based drug delivery system to maintain the optimum Ph level in the vagina. The de.
